乳腺癌组织和血浆中分泌球蛋白家族2A成员2的表达分析

目的探讨分泌球蛋白家族2A成员2(SCGB2A2)在乳腺癌组织和血浆中的表达及对肺内转移性乳腺癌的诊断意义。方法采用免疫组织化学法检测SCGB2A2在31例乳腺癌、42例肺癌、38例乳腺癌肺转移和29例肺转移性腺癌中的表达。酶联免疫吸附(ELISA)法定量测定87例乳腺癌患者、21例乳腺癌肺转移、26例乳腺纤维腺瘤患者和30例健康志愿者血浆中SCGB2A2含量。结果 SCGB2A2在乳腺癌中阳性表达率为64.5%(20/31),在乳腺癌肺转移患者组织中表达为68.4(26/38),而肺转移性腺癌中不表达。SCGB2A2鉴别乳腺癌肺转移和肺原发癌的敏感性为63.9%,特异性为81.8%。乳腺癌组患者术前血浆SCGB2A2水平高于纤维腺瘤组和健康对照组(均P<0.05)。结论 SCGB2A2在乳腺癌患者中特异性高表达,可作为鉴别乳腺癌肺转移及肺转移性腺癌的特异指标,且有可能作为判断乳腺癌外周血微转移的标志物。

Analysis the expression of SCGB2A2 in the tissues and plasma of breast carcinoma

Objective To investigate the expression of SCGB2A2 in the tissues and plasma of breast carcinoma and clinical value on pulmonary metastatic breast carcinoma. Methods The expression of SCGB2A2 protein was examined in 31 cases of primary breast carcinoma, 48 patients with pulmonary metastatic breast carcinoma, 39 cases of pulmonary metastatic adenocarcinom other than breast origin pathologically confirmed by immunohistochemical staining technique. The SCGB2A2 level was detected in 87 patients with breast carcinoma, 26 cases of mammary fibroadenoma and 30 healthy volunteers by enzyme-linked im- munosorbent assay（ELISA）. Results SCGB2A2 was positively expressed in 64. 5% of breast carcinoma, higher than that of other origins, and was not detected in other adenocarcinomas. Twenty-six of thirty-eight patients with pulmonary metastatic breast carcinoma were tested SCGB2A2 by immunohistochemistry. How- ever, no expression of SCGB2A2 was detected in pulmonary metastatic adenocarcinom tissue specimens. Its sensitivity and specifcity were 63.9% and 81.8% , respectively in differential diagnosis of pulmonary metastatic breast carcinoma and pulmonary metastatic adenocarcinom. The SCGB2A2 level in patients with breast carcinoma was significantly higher than that of patients with mammary fibroadenoma and healthy volunteers （ P 〈 0. 05 ）. Conclusions SCGB2A2 could be promsing biomarker for differential diagnosis of pulmonary metastatic breast carcinoma for its higher level in primary breast carcinoma than that in primary pulmonary carcinoma. The rising of SCGB2A2 in peripheral blood could be assessed as a marker in detecting micrometastases for breast carcinoma.